| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
3,012 |
2,358 |
$1.76M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,684 |
4,051 |
$1.70M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,220 |
982 |
$1.14M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,430 |
3,025 |
$804K |
| 80053 |
Comprehensive metabolic panel |
8,026 |
6,629 |
$601K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
494 |
454 |
$526K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
9,627 |
7,958 |
$426K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
2,448 |
2,268 |
$335K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,255 |
1,762 |
$245K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
4,915 |
1,826 |
$239K |
| 36415 |
Collection of venous blood by venipuncture |
9,619 |
8,271 |
$228K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,128 |
1,649 |
$213K |
| 80306 |
|
1,365 |
1,178 |
$171K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
849 |
606 |
$166K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
525 |
503 |
$163K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,944 |
1,699 |
$152K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,884 |
1,450 |
$151K |
| G0378 |
Hospital observation service, per hour |
36 |
27 |
$147K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,636 |
2,102 |
$135K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,480 |
2,389 |
$124K |
| 71046 |
Radiologic examination, chest; 2 views |
1,270 |
1,174 |
$121K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,969 |
1,779 |
$120K |
| 80061 |
Lipid panel |
1,610 |
1,578 |
$103K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
2,350 |
769 |
$100K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
854 |
600 |
$96K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,061 |
2,009 |
$81K |
| 81001 |
|
3,515 |
3,080 |
$75K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
2,169 |
900 |
$75K |
| 87486 |
|
525 |
503 |
$63K |
| 83690 |
|
1,093 |
937 |
$61K |
| 70450 |
Computed tomography, head or brain; without contrast material |
156 |
137 |
$59K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
766 |
685 |
$58K |
| 87581 |
|
525 |
503 |
$58K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,461 |
1,319 |
$54K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
513 |
449 |
$50K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
581 |
561 |
$49K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
579 |
560 |
$49K |
| 86140 |
|
1,509 |
1,304 |
$49K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
508 |
411 |
$49K |
| 84484 |
|
810 |
585 |
$42K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
407 |
394 |
$38K |
| 87186 |
|
725 |
609 |
$37K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
374 |
333 |
$36K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
601 |
573 |
$35K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,154 |
973 |
$34K |
| 97161 |
|
368 |
356 |
$33K |
| 83735 |
|
695 |
531 |
$32K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,619 |
1,315 |
$31K |
| 81003 |
|
1,085 |
874 |
$30K |
| 83880 |
|
215 |
180 |
$28K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
97 |
92 |
$28K |
| 83605 |
|
536 |
460 |
$25K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
368 |
299 |
$25K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
856 |
703 |
$23K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,037 |
850 |
$22K |
| 84439 |
|
368 |
363 |
$20K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
345 |
322 |
$18K |
| 85652 |
|
626 |
598 |
$16K |
| 71045 |
Radiologic examination, chest; single view |
350 |
301 |
$16K |
| 81025 |
|
483 |
459 |
$15K |
| 84145 |
|
72 |
60 |
$13K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
23 |
19 |
$12K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
1,026 |
627 |
$12K |
| 87536 |
|
67 |
64 |
$11K |
| 97035 |
|
535 |
153 |
$11K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
118 |
81 |
$10K |
| 82962 |
|
841 |
583 |
$10K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
115 |
111 |
$9K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,560 |
1,322 |
$9K |
| 97010 |
|
916 |
311 |
$9K |
| 84703 |
|
168 |
154 |
$8K |
| 82728 |
|
151 |
138 |
$7K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
132 |
127 |
$7K |
| 85027 |
|
116 |
108 |
$6K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
93 |
43 |
$5K |
| 85610 |
|
203 |
154 |
$4K |
| 82805 |
|
32 |
25 |
$4K |
| 82652 |
|
95 |
93 |
$4K |
| 87070 |
|
40 |
36 |
$3K |
| 82607 |
|
63 |
61 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,102 |
992 |
$3K |
| 87205 |
|
73 |
67 |
$3K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
273 |
183 |
$2K |
| 96376 |
|
44 |
36 |
$2K |
| 97602 |
|
47 |
12 |
$2K |
| 86803 |
|
44 |
41 |
$2K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
55 |
41 |
$2K |
| Q3014 |
Telehealth originating site facility fee |
88 |
84 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
106 |
93 |
$2K |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
38 |
37 |
$1K |
| 82570 |
|
31 |
29 |
$1K |
| J2704 |
Injection, propofol, 10 mg |
158 |
136 |
$1K |
| 87077 |
|
14 |
13 |
$914.79 |
| 36416 |
|
35 |
27 |
$711.76 |
| 86780 |
|
16 |
14 |
$686.45 |
| 87480 |
|
12 |
12 |
$666.97 |
| 85379 |
|
15 |
12 |
$652.41 |
| 87340 |
|
14 |
14 |
$532.78 |
| 87510 |
|
12 |
12 |
$510.39 |
| 87899 |
|
26 |
26 |
$441.40 |
| 87088 |
|
17 |
12 |
$312.07 |
| 86901 |
|
13 |
12 |
$266.76 |
| 81015 |
|
103 |
87 |
$265.45 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
28 |
27 |
$167.05 |
| 95250 |
|
19 |
18 |
$67.74 |
| A9270 |
Non-covered item or service |
185 |
117 |
$60.98 |
| 96127 |
|
33 |
28 |
$59.10 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
13 |
12 |
$56.02 |
| 87806 |
|
26 |
26 |
$48.48 |
| 80320 |
|
548 |
465 |
$0.00 |
| 80329 |
|
30 |
13 |
$0.00 |
| T1015 |
Clinic visit/encounter, all-inclusive |
78 |
57 |
$0.00 |